GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases

Mitochondrion

Volumn 20, Issue , 2015, Pages 34-42

  Fujita, Yasunori ^a   Ito, Masafumi ^a   Kojima, Toshio ^b   Yatsuga, Shuichi ^c   Koga, Yasutoshi ^c   Tanaka, Masashi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Cybrid; GDF15; Microarray; Mitochondrial diseases; Pyruvate

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; GROWTH DIFFERENTIATION FACTOR 15; INHIBIN; INHIBIN BETA E; LACTIC ACID; PYRUVIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE EXPRESSION; HUMAN; HUMAN CELL; HYBRID CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN SECRETION; DRUG MONITORING; GENE EXPRESSION PROFILING; METABOLISM; MITOCHONDRIAL DISEASES; PROCEDURES;

BIOLOGICAL MARKERS; DRUG MONITORING; GENE EXPRESSION PROFILING; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MICROARRAY ANALYSIS; MITOCHONDRIAL DISEASES; PYRUVIC ACID;

EID: 84910655212     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2014.10.006     Document Type: Article

References (42)

1. Baek S.J., Wilson L.C., Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002, 23:425-434.
2. Behan A., Doyle S., Farrell M. Adaptive responses to mitochondrial dysfunction in the rho degrees Namalwa cell. Mitochondrion 2005, 5:173-193.
3. Bruning A., Matsingou C., Brem G.J., Rahmeh M., Mylonas I. Inhibin beta E is upregulated by drug-induced endoplasmic reticulum stress as a transcriptional target gene of ATF4. Toxicol. Appl. Pharmacol. 2012, 264:300-304.
4. Chomyn A., Martinuzzi A., Yoneda M., Daga A., Hurko O., Johns D., Lai S.T., Nonaka I., Angelini C., Attardi G. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4221-4225.
5. Crimi M., Bordoni A., Menozzi G., Riva L., Fortunato F., Galbiati S., Del Bo R., Pozzoli U., Bresolin N., Comi G.P. Skeletal muscle gene expression profiling in mitochondrial disorders. Faseb J. 2005, 19:866-868.
6. Davis R.L., Liang C., Edema-Hildebrand F., Riley C., Needham M., Sue C.M. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 2013, 81:1819-1826.
7. Dombroski B.A., Nayak R.R., Ewens K.G., Ankener W., Cheung V.G., Spielman R.S. Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. Am. J. Hum. Genet. 2010, 86:719-729.
8. Dostalova I., Roubicek T., Bartlova M., Mraz M., Lacinova Z., Haluzikova D., Kavalkova P., Matoulek M., Kasalicky M., Haluzik M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur. J. Endocrinol. 2009, 161:397-404.
9. Exner N., Lutz A.K., Haass C., Winklhofer K.F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31:3038-3062.
10. Fuchs T., Trollor J.N., Crawford J., Brown D.A., Baune B.T., Samaras K., Campbell L., Breit S.N., Brodaty H., Sachdev P., Smith E. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell 2013, 12:882-889.
11. Fujita Y., Ito M., Nozawa Y., Yoneda M., Oshida Y., Tanaka M. CHOP (C/EBP homologous protein) and ASNS (asparagine synthetase) induction in cybrid cells harboring MELAS and NARP mitochondrial DNA mutations. Mitochondrion 2007, 7:80-88.
12. Goto Y., Nonaka I., Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
13. Goto Y., Horai S., Matsuoka T., Koga Y., Nihei K., Kobayashi M., Nonaka I. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992, 42:545-550.
14. Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., Sadri N., Yun C., Popko B., Paules R., Stojdl D.F., Bell J.C., Hettmann T., Leiden J.M., Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 2003, 11:619-633.
15. Hashimoto O., Sekiyama K., Matsuo T., Hasegawa Y. Implication of activin E in glucose metabolism: transcriptional regulation of the inhibin/activin betaE subunit gene in the liver. Life Sci. 2009, 85:534-540.
16. Jiang H.Y., Wek S.A., McGrath B.C., Lu D., Hai T., Harding H.P., Wang X., Ron D., Cavener D.R., Wek R.C. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol. 2004, 24:1365-1377.
17. Jousse C., Deval C., Maurin A.C., Parry L., Cherasse Y., Chaveroux C., Lefloch R., Lenormand P., Bruhat A., Fafournoux P. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. J. Biol. Chem. 2007, 282:15851-15861.
18. Kalko S.G., Paco S., Jou C., Rodriguez M.A., Meznaric M., Rogac M., Jekovec-Vrhovsek M., Sciacco M., Moggio M., Fagiolari G., De Paepe B., De Meirleir L., Ferrer I., Roig-Quilis M., Munell F., Montoya J., Lopez-Gallardo E., Ruiz-Pesini E., Artuch R., Montero R., Torner F., Nascimento A., Ortez C., Colomer J., Jimenez-Mallebrera C. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 2014, 15:91.
19. Kami K., Fujita Y., Igarashi S., Koike S., Sugawara S., Ikeda S., Sato N., Ito M., Tanaka M., Tomita M., Soga T. Metabolomic profiling rationalized pyruvate efficacy in cybrid cells harboring MELAS mitochondrial DNA mutations. Mitochondrion 2012, 12:644-653.
20. Kempf T., Horn-Wichmann R., Brabant G., Peter T., Allhoff T., Klein G., Drexler H., Johnston N., Wallentin L., Wollert K.C. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin. Chem. 2007, 53:284-291.
21. Kirino Y., Yasukawa T., Ohta S., Akira S., Ishihara K., Watanabe K., Suzuki T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15070-15075.
22. Koga Y., Povalko N., Katayama K., Kakimoto N., Matsuishi T., Naito E., Tanaka M. Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1alpha gene. Brain Dev. 2012, 34:87-91.
23. Lee J.I., Dominy J.E., Sikalidis A.K., Hirschberger L.L., Wang W., Stipanuk M.H. HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway. Physiol. Genomics 2008, 33:218-229.
24. Li J., Yang L., Qin W., Zhang G., Yuan J., Wang F. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. PLoS One 2013, 8:e65549.
25. Lopez-Otin C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell 2013, 153:1194-1217.
26. Martin S.D., McGee S.L. The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes. Biochim. Biophys. Acta 2014, 1840:1303-1312.
27. Pavlakis S.G., Phillips P.C., DiMauro S., De Vivo D.C., Rowland L.P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann. Neurol. 1984, 16:481-488.
28. Rouschop K.M., van den Beucken T., Dubois L., Niessen H., Bussink J., Savelkouls K., Keulers T., Mujcic H., Landuyt W., Voncken J.W., Lambin P., van der Kogel A.J., Koritzinsky M., Wouters B.G. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest. 2010, 120:127-141.
29. Rzymski T., Milani M., Pike L., Buffa F., Mellor H.R., Winchester L., Pires I., Hammond E., Ragoussis I., Harris A.L. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 2010, 29:4424-4435.
30. Saito K., Kimura N., Oda N., Shimomura H., Kumada T., Miyajima T., Murayama K., Tanaka M., Fujii T. Pyruvate therapy for mitochondrial DNA depletion syndrome. Biochim. Biophys. Acta 2012, 1820:632-636.
31. Sermeus A., Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis. 2011, 2:e164.
32. Sperka T., Wang J., Rudolph K.L. DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol. 2012, 13:579-590.
33. Suomalainen A., Elo J.M., Pietilainen K.H., Hakonen A.H., Sevastianova K., Korpela M., Isohanni P., Marjavaara S.K., Tyni T., Kiuru-Enari S., Pihko H., Darin N., Ounap K., Kluijtmans L.A., Paetau A., Buzkova J., Bindoff L.A., Annunen-Rasila J., Uusimaa J., Rissanen A., Yki-Jarvinen H., Hirano M., Tulinius M., Smeitink J., Tyynismaa H. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol. 2011, 10:806-818.
34. Tanaka M., Nishigaki Y., Fuku N., Ibi T., Sahashi K., Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 2007, 7:399-401.
35. Teske B.F., Wek S.A., Bunpo P., Cundiff J.K., McClintick J.N., Anthony T.G., Wek R.C. The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol. Biol. Cell 2011, 22:4390-4405.
36. Tyynismaa H., Carroll C.J., Raimundo N., Ahola-Erkkila S., Wenz T., Ruhanen H., Guse K., Hemminki A., Peltola-Mjosund K.E., Tulkki V., Oresic M., Moraes C.T., Pietilainen K., Hovatta I., Suomalainen A. Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 2010, 19:3948-3958.
37. Unsicker K., Spittau B., Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013, 24:373-384.
38. Welsh J.B., Sapinoso L.M., Kern S.G., Brown D.A., Liu T., Bauskin A.R., Ward R.L., Hawkins N.J., Quinn D.I., Russell P.J., Sutherland R.L., Breit S.N., Moskaluk C.A., Frierson H.F., Hampton G.M. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3410-3415.
39. Wiklund F.E., Bennet A.M., Magnusson P.K., Eriksson U.K., Lindmark F., Wu L., Yaghoutyfam N., Marquis C.P., Stattin P., Pedersen N.L., Adami H.O., Gronberg H., Breit S.N., Brown D.A. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010, 9:1057-1064.
40. Yang H., Filipovic Z., Brown D., Breit S.N., Vassilev L.T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2003, 2:1023-1029.
41. Yasukawa T., Suzuki T., Ueda T., Ohta S., Watanabe K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs(Leu)(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J. Biol. Chem. 2000, 275:4251-4257.
42. Zhang X.D., Qin Z.H., Wang J. The role of p53 in cell metabolism. Acta Pharmacol. Sin. 2010, 31:1208-1212.